Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease

Chest

Volumn 148, Issue 2, 2015, Pages 499-506

  Philley, Julie V ^a   Wallace, Richard J ^a,b   Benwill, Jeana L ^a,b   Taskar, Varsha ^a   Brown Elliott, Barbara A ^b   Thakkar, Foram ^a   Aksamit, Timothy R ^c   Griffith, David E ^a  

^a Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; BEDAQUILINE; CEFOXITIN; ERYTHROMYCIN; ETHAMBUTOL; IMIPENEM; LINEZOLID; MACROLIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANOREXIA; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; ATAXIA; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIOSTASIS; BLURRED VISION; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IN VITRO STUDY; INSOMNIA; LONG QT SYNDROME; MALE; MICROBIOLOGICAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMACH PAIN; TINNITUS; VOMITING; AGED; CHEMICALLY INDUCED; COHORT ANALYSIS; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADULT; AGED; ANOREXIA; ANTITUBERCULAR AGENTS; ARTHRALGIA; COHORT STUDIES; DIARYLQUINOLINES; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NAUSEA; SALVAGE THERAPY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84939229750     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2764     Document Type: Article

References (31)

1. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008; 178 (10): 1066-1074.
2. Aksamit TR. M ycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med. 2002; 23 (3): 643-653.
3. Wallace RJ Jr. Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994; 149 (5): 1335-1341.
4. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP; Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest. 1995; 107 (4): 1035-1040.
5. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodefi ciency virus. Clin Infect Dis. 1996; 23 (5): 983-989.
6. Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [published correction appears in Am J Respir Crit Care Med. 2007;175(7):744-745]. Am J Respir Crit Care Med. 2007; 175 (4): 367-416.
7. Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent antituberculosis drugs. Future Microbiol. 2010; 5 (6): 849-858.
8. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010; 375 (9728): 1798-1807.
9. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009; 9 (3): 153-161.
10. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007; 51 (11): 4202-4204.
11. Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K. ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother. 2009; 53 (11): 4927-4929.
12. Diacon AH, Pym A, Grobusch MP, et al; TMC207-C208 Study Group. Multidrugresistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371 (8): 723-732.
13. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis . M MWR Recomm Rep. 2013; 62 (RR-09): 1-12.
14. Cox E, Laessig K. FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med. 2014; 371 (8): 689-691.
15. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006; 174 (8): 928-934.
16. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014; 11 (1): 30-35.
17. Mahajan R. Bedaquiline: first FDAapproved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013; 3 (1): 1-2.
18. Prammananan T, Sander P, Brown BA, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis. 1998; 177 (6): 1573-1581.
19. Woods G, Brown-Elliott B, Conville PS, et al. S usceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard-Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2011. CLSI document M24-A2.
20. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm (41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae . A ntimicrob Agents Chemother. 2009; 53 (4): 1367-1376.
21. Wallace RJ Jr. Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus . A ntimicrob Agents Chemother. 1996; 40 (7): 1676-1681.
22. Wallace RJ Jr. Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014; 146 (2): 276-282.
23. Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol. 2003; 41 (12): 5699-5708.
24. Steingrube VA, Gibson JL, Brown BA, et al. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. J Clin Microbiol. 1995; 33 (1): 149-153.
25. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993; 31 (2): 175-178.
26. Olivier K, Daley C, Smith A, Jones P, Davis M, Guntapaldi T, et al. A controlled study of liposomal amikacin for inhalation in patients with recalcitrant nontuberculous mycobacterial lung disease. Paper presented at: American Thoracic Society Annual Meeting; May 16-25, 2014; San Diego, CA.
27. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014; 12 (2): 121-127.
28. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366 (20): 1881-1890.
29. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events aft er clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013; 346: f1235.
30. Milano A, Pasca MR, Provvedi R, et al. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb). 2009; 89 (1): 84-90.
31. Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J. 2015; 45 (2): 554-557.